Gwo‐Yaw Ho
A5056999735- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Proteoglycans and glycosaminoglycans research
- DNA Repair Mechanisms
- Sarcoma Diagnosis and Treatment
- Fibroblast Growth Factor Research
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Microtubule and mitosis dynamics
- Plant Virus Research Studies
- CRISPR and Genetic Engineering
- Cancer Mechanisms and Therapy
- Cancer-related molecular mechanisms research
- Advances in Oncology and Radiotherapy
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Economic and Financial Impacts of Cancer
- Ubiquitin and proteasome pathways
- Gastrointestinal Bleeding Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Kruppel-like factors research
Walter and Eliza Hall Institute of Medical Research
2016-2025
The University of Melbourne
2017-2025
Monash University
2020-2025
Monash Health
2020-2025
Royal Women's Hospital
2017-2023
Monash Medical Centre
2020
Peter MacCallum Cancer Centre
2017-2019
The University of Queensland
2015-2016
Mater Health Services
2015-2016
Mater Adult Hospital
2015
Abstract High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism. We sequenced core pathway 12 pairs pretreatment postprogression tumor biopsy samples collected from patients ARIEL2 Part 1, a phase II study the PARPi rucaparib...
Abstract Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical importance. Here we show that quantitative BRCA1 methylation analysis provides new insight into PARPi response in preclinical models and cancer patients. The 12 HGSOC patient-derived xenografts (PDX) the rucaparib was assessed, variable dose-dependent responses observed chemo-naive BRCA1/2 -mutated PDX, no PDX...
Abstract Mucinous ovarian carcinoma (MOC) is a unique subtype of cancer with an uncertain etiology, including whether it genuinely arises at the ovary or metastatic disease from other organs. In addition, molecular drivers invasive progression, high-grade and are poorly defined. We perform genetic analysis MOC across all histological grades, benign borderline mucinous tumors, compare these to tumors potential extra-ovarian sites origin. Here we show that distinct supports progressive model...
In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defective homologous recombination and emerging biomarkers PARP inhibitor (PARPi) sensitivity. promoter methylation (meRAD51C) is detected at similar frequencies to mutations, yet its effects on PARPi responses remain unresolved.In this study, three HGSC patient-derived xenograft (PDX) models with most or all examined CpG sites the show PARPi. Both complete heterogeneous...
Abstract Ovarian cancer (OC) poses a significant clinical challenge due to its high recurrence rates and resistance standard therapies, particularly in advanced stages where is common, treatment predominantly palliative. Personalized treatments, while effective other cancers, remain underutilized OC lack of reliable biomarkers predicting outcomes. Accordingly, precision medicine approaches are limited, with PARP inhibitors showing efficacy only specific genetic contexts. Drug repurposing...
Ovarian carcinosarcoma (OCS) is an aggressive and rare tumor type with limited treatment options. OCS hypothesized to develop via the combination theory, a single progenitor resulting in carcinomatous sarcomatous components, or alternatively conversion component developing from through epithelial-to-mesenchymal transition (EMT). In this study, we analyzed DNA variants isolated carcinoma sarcoma components show that 18 women monoclonal. RNA sequencing indicated were more mesenchymal when...
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy with over 80% of cases already disseminated at diagnosis and facing a dismal five-year survival rate 35%. EOC cells often spread to greater omentum where they take-up cholesterol. Excessive amounts cholesterol can be cytocidal, suggesting that efflux through transporters may important maintain homeostasis, this explain observation high expression ATP-binding cassette A1 (ABCA1) transporter has been associated poor...
Current first-line systemic treatment in most patients with metastatic hormone receptor-positive, HER-2 negative breast cancer is an aromatase inhibitor combination a cyclin dependant kinase (CDK) 4/6 inhibitor. Frequently, these require palliative radiotherapy (RT) for symptomatic disease management. There paucity of data on the safety combining CDK RT, conflicting case reports literature. We report 5 cases at our institution where enhanced toxicity was observed when doses RT delivered...
<h2>Summary</h2> High-grade serous ovarian cancers (HGSOCs) with homologous recombination deficiency (HRD) are initially responsive to poly (ADP-ribose) polymerase inhibitors (PARPi), but resistance ultimately emerges. HGSOC <i>CCNE1</i> amplification (<i>CCNE1</i><sup>amp</sup>) associated PARPi and platinum treatments. High replication stress in HRD <i>CCNE1</i><sup>amp</sup> leads increased reliance on checkpoint kinase 1 (CHK1), a key regulator of cell cycle progression the response....
splice isoforms Δ11 and Δ11q can contribute to PARP inhibitor (PARPi) resistance by splicing-out the mutation-containing exon, producing truncated, partially-functional proteins. However, clinical impact underlying drivers of
Epithelial ovarian cancer (EOC) is a complex disease comprising discrete histological and molecular subtypes, for which survival rates remain unacceptably low. Tailored approaches this deadly heterogeneous are urgently needed. Efflux pumps belonging to the ATP-binding cassette (ABC) family of transporters known roles in both drug resistance biology also highly targetable. Here we have investigated association ABCC4/MRP4 expression clinical outcome its biological function endometrioid serous...
Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have de novo platinum-refractory disease.To determine the potential anti-microtubule agent (AMA) (paclitaxel, vinorelbine eribulin) in platinum-resistant or refractory (PRR) HGSC by assessing patient-derived xenograft (PDX) models HGSC.Of 13 PRR PDX, six were primary PRR,...
Metastatic breast cancer (mBC) guidelines recommend multidisciplinary meetings (MDM), but there is limited research on their impact. This prospective study examines the impact of an mBC MDM management plans, implementation rate, and costs benefits at Australian metropolitan center.